"Designing Growth Strategies is in our DNA"

Cardiac Biomarkers Market Size, Share and Global Trend By Type (Troponin, Creatine kinase-MB (CK-MB), B-type Natriuretic Peptide (BNP), and N-terminal pro b-type natriuretic peptide (NT-proBNP), Myoglobin), By Application (Acute Coronary Syndrome, Myocardial Infarction, Congestive Heart Failure), By End User (Hospitals, Diagnostic Centers, Homecare Settings) and Geography Forecast till 2026

Region : Global | Published Date: Ongoing | Report ID: FBI101233| Status : Upcoming



Biomarkers play a crucial role in the management, diagnosis, risk stratification, and clinical decision-making in the patients suffering from chronic diseases. Cardiac biomarkers are quantifiable, which are detected in the blood and help as indices for pathological and physiological assessment by a specialized immunoassay.

In January 2017 Roche received the 510(k) clearance for Elecsys Troponin T Gen 5 STAT (TnT Gen 5 STAT) blood test for patients with a suspected heart attack. Investments by key market players in the research and development of the novel cardiac markers is one of the significant factor boosting the cardiac biomarkers market growth.

To get information on various segments, share your queries with us

The increasing demand for cardiac biomarkers is due to the increasing prevalence of cardiovascular disease subsequently increasing the demand for the cardiac biomarkers for diagnosis. Furthermore, technological advancements in the development of cardiovascular biomarkers, high prevalence of Acute Coronary Syndrome (ACS) and growing number of new product launches by the key market players are some of the factors propelling the cardiac biomarkers market growth.

Additionally, rising demand for point of care testing kits, along with the high specificity and sensitivity of cardiac biomarkers in the detection of cardiovascular diseases are some of the major elements driving the growth of the global cardiac biomarkers market.

The major factors limiting the growth of the global cardiac biomarkers market are the time needed for the biomarkers to be reflected in the blood, and the inadequate reimbursement policies especially in emerging countries.

Key Players Covered

The major companies covered in the global cardiac biomarkers market report F. Hoffmann-La Roche Ltd, Abbott, Siemens Healthcare GmbH, Beckman Coulter, Inc., bioMérieux SA, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Randox Laboratories Ltd., Thermo Fisher Scientific, and others.




By Type

· Troponin

· Creatine kinase-MB (CK-MB)

· B-type Natriuretic Peptide (BNP), and N-terminal pro b-type natriuretic peptide (NT-proBNP)

· Myoglobin

· Others

By Application

· Acute Coronary Syndrome

· Myocardial Infarction

· Congestive Heart Failure

· Others

By End User

· Hospitals

· Diagnostic Centers

· Homecare Settings

· Others

By Geography

· North America (USA and Canada)

· Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)

· Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)

· Latin America (Brazil, Mexico and Rest of Latin America)

· Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)


As per the current cardiac biomarkers market trends, acute coronary syndrome segment among the applications is projected to register comparatively higher CAGR in the global market owing to increasing the prevalence of acute coronary syndrome and increased investment by cardiac health institutes in biomarker testing of low risk patients of ACS in order to identify and diagnose the disease at early stage. 

Key Insights

  • Prevalence of Cardiovascular Disease by Key Countries

  • Regulatory Scenario by Key Countries

  • Overview of Investments for Research & Development of Cardiac Biomarkers

  • Recent Advancements in the Global Cardiac Biomarkers Market

  • Key Mergers and Acquisitions

Regional Analysis

The global cardiac biomarkers market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the cardiac biomarkers market in 2018. According to the Centers for Disease Control and Prevention (CDC), about 610,000 individuals in the U.S. die due to heart disease, equivalent to 1 in 4 deaths. The increasing prevalence of cardiovascular disease along with increased demand for the disease diagnostics in the region are some of the major factors attributing the growth of the cardiac biomarkers in the region. Europe and the Asia Pacific are anticipated to grow at a significant CAGR, during the forecast period of 2019-2026. The Middle East and Africa and Latin America are estimated to grow at a relatively lower CAGR during the forecast period.

Cardiac Biomarkers Industry Developments

  • In July 2018, Siemens Healthineers received approval from U.S. Food and Drug Administration (FDA) for high-sensitivity troponin I assays (TnIH) for the Atellica IM and ADVIA Centaur XP/XPT in vitro diagnostic analyzers from for the early diagnosis of myocardial infarctions.
  • In January 2017, Roche received the 510(k) clearance for Elecsys Troponin T Gen 5 STAT (TnT Gen 5 STAT) blood test for patients with a suspected heart attack.

Cardiac Biomarkers Market Size, Share and Global Industry Trend Forecast till 2026
  • PDF
  • 2018
  • 2014-2017


  • 4850

Healthcare Clients


Client Testimonials

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . More info.